Qubit Pharmaceuticals

🌍 Qubit Pharmaceuticals is headed to BIO-Europe in Stockholm, November 4–6! 🌍 Join us at BIO-Europe in Stockholm to explore how Qubit Pharmaceuticals is using Quantum Science and Computing to drive innovation in drug discovery, especially for complex targets like RNA. Our team, including Sara Dolcetti, will be on-site, eager to connect with innovators and partners! Let’s discuss our latest breakthroughs in RNA-targeted therapeutics and see how our advanced technologies could support your pipeline. Have you checked out our blog on our latest RNA research yet? 👉 https://loom.ly/ZviMPf8 If you’re attending, let’s meet in Sweden to explore new frontiers in drug discovery! #BIOEurope #DrugDiscovery #QuantumScience #QubitPharmaceuticals

🌏 We’re pleased to announce that Robert Marino, CEO of Qubit Pharmaceuticals, will deliver the closing keynote at AusBiotech 2024 in Melbourne. 🇦🇺 On Friday, Nov 1st, at 3 PM, Robert will present "Synergy in Science: Integrating AI, Robotics, and Quantum Computing for Drug Discovery". His keynote will address the practical applications of combining these advanced technologies in accelerating drug discovery, a critical area for innovation. As #AusBiotech2024 gathers over 260 speakers and 60 sessions covering the latest in #biotechnology, this talk aims to underscore how integration across disciplines can drive impactful solutions in #pharmaceuticalresearch. This year’s program has been crafted to serve the life sciences ecosystem with perspectives from global and local leaders, making it one of the region’s premier biotech events. We look forward to sharing insights on the potential of AI, robotics, and quantum computing to reshape and streamline drug development. All information here: https://loom.ly/Bj2nN48 #DrugDiscovery #QuantumAidedDrugDesign

🧬 Unlocking RNA Targets: Advancing Drug Discovery with Cutting-Edge Simulations 💫 At Qubit Pharmaceuticals, we’ve made a breakthrough in computational drug design, tackling one of the biggest challenges in modern medicine: RNA-targeted therapeutics. By combining cutting-edge technologies like: 🔸 Lambda-ABF for precision binding affinity prediction 🔸 Tinker-HP for enhanced molecular dynamics 🔸 Advanced sampling techniques in combination with machine learning to capture complex RNA conformational changes …we're paving the way for faster, more accurate drug discovery, with unprecedented insights into RNA-small molecule interactions. RNA-targeting therapeutics also expand the druggable target space in the human genome from 0.2% to ~70%, offering an attractive alternative to reach traditionally undruggable proteins! 📰Our latest blog explores how our advanced methods open new possibilities for designing drugs to treat the most difficult diseases. The blog is based on a scientific publication, currently available as a preprint, showcasing these innovations. A special thanks to our partners Bpifrance, European Innovation Council and SMEs Executive Agency (EISMEA) , #FRANCE 2030, GENCI , Secrétariat général pour l'investissement, Région Île-de-France, and Sorbonne Université, as well as our investors Quantonation, XAnge & Omnes. And, of course, 👏massive congratulations👏 to the authors, Narjes A. , Chengwen Liu, Florent Hédin, Jérôme Hénin, Jay Ponder, Pengyu Ren, Jean-Philip Piquemal, Louis Lagardère, and Krystel El Hage, PhD El Hage for their remarkable work! 👉 Read more and discover how we're revolutionizing RNA drug discovery: https://loom.ly/SdIjUxA 👉 Straight to the preprint? Sure! https://loom.ly/Al9PcUU Pharmaceuticals and biotech companies seeking to unlock new treatment possibilities, let’s collaborate and make the next breakthrough together - Reach out to us today! #ComputationalChemistry #QuantumAidedDrugDesign #RNAtherapeutics #DrugDiscovery

🌍 Join us at SWITCH Singapore 2024, a premier global innovation event spotlighting transformative technologies like quantum computing and AI! Our CEO, Robert Marino, will be speaking at the “Meet Early Adopters for Quantum Computing in Finance and Biotech” panel alongside top industry experts: - A/Prof Ying Chen, Director of Centre for Quantitative Finance, National University of Singapore - Mr. Jorden Seet, Head of Emerging Technologies Engineering, OCBC - Dr. Jayne Thompson, Group Manager Quantum Algorithms, A*Star - Institute of High Performance Computing (IHPC) - Dr. Enrico Petretto, Director, Centre for Computational Biology, Duke-NUS Medical School 🗓 Date: October 29, 2024 🕒 Time: 2:30 PM - 3:15 PM SGT 📍 Venue: Sands Expo & Convention Center, Beyond Stage We’ll be discussing how #QuantumComputing is reshaping industries like #biotech and finance, solving complex challenges from #DrugDiscovery to risk management. 🔗 Shoutout to the organizers and to our partners @Christophe Jurczak and. @Quantonation who we look forward to seeing there! #SWITCHSingapore24 #DeepTech #SWITCH2024

📯NEW RESEARCH PAPER IN PREPRINT! We’ve just submitted our latest research paper, "The velocity jump Langevin process and its splitting scheme: long time convergence and numerical accuracy," to preprint. This paper introduces a novel hybrid method that combines velocity jumps—sudden changes in particle speed—with Langevin diffusion, a well-established approach for molecular simulations. Our findings show that this method improves simulation speed without sacrificing accuracy, enabling faster results while maintaining precision. A big congratulations to the authors Nicolaï Gouraud (Qubit Pharmaceuticals, Sorbonne Université), Lucas Journel ( Université de Neuchâtel), and Monmarché Pierre (Sorbonne Université) for their fantastic work! ▶️Read the paper here: https://loom.ly/sejn_1I While this is a theory-focused paper, it lays the mathematical foundation for practical advancements. A companion paper will soon be released, detailing the implementation of this method in TinkerHP, our platform designed for high-performance molecular simulations—and we expect to have exciting results to share! 🤔But first, why are mathematics so important for drug discovery? Mathematics is at the core of innovation in in silico drug discovery. It provides the rigorous frameworks necessary to model complex molecular behaviors accurately, enabling more efficient simulations. By enhancing both speed and accuracy, these mathematical models allow researchers to explore a broader range of drug candidates, ultimately accelerating the drug development process. Stay tuned for more updates on both papers! #InSilicoDrugDiscovery #QuantumChemistry #ComputationalChemistry #Mathematics

Last week, our CEO Robert Marino had the pleasure of representing Qubit Pharmaceuticals at a French Tech 2030 event. 🚀 As a company dedicated to leveraging #quantumcomputing to design novel molecules for #drugdiscovery, we are thrilled to be part of a community pushing the boundaries of innovation in France. We extend our heartfelt thanks to the #France2030 program, Bruno Bonnell from the Secretary general for investment, and Bpifrance for their unwavering support in driving forward cutting-edge technologies and innovation. The backing of such visionary initiatives, allows us to advance our mission of pioneering quantum-aided drug design, developing better treatments for any target and every patient. We also take this opportunity to congratulate Clara Chappaz on her new role as Secretary of State for Artificial Intelligence and Digital Affairs, and Julie Huguet, the new Director of La French Tech. 👏 👏 Together, as an ecosystem, we are shaping the future of science and innovation, so we give a special a shoutout to all our fellow laureates! #QuantumComputing #DrugDiscovery #FrenchTech2030 #Innovation #Healthcare

We had a fantastic time at #BiotechX2024 in Basel! Andrea de Souza and Dina Ahdab (EL), PhD, engaged in insightful discussions and showcased our advances in quantum-aided drug design. The event was full of innovation, and we’re excited about the potential collaborations on the horizon! From presenting posters on targeting RNA with small molecules, and "AMOEBA Polarizable Molecular Dynamics Simulations of Guanine Quadruplexes" to a presentation on the #QuantumPharma track on Exploring the Future of Quantum-Aided Drug Design for Pharmaceuticals Research, it was inspiring to be part of the conversation shaping the future of healthcare and technology. Thank you to everyone who joined us and for all the meaningful conversations! #DrugDiscovery #QuantumAidedDrugDesign #QuantumComputingInPharma

🌟Qubit Pharmaceuticals - Rising Star in the European Quantum Landscape🌟 We're proud to share that Qubit Pharmaceuticals has been named one of the four rising stars in the European quantum startup ecosystem, according to Sifted's Quantum Computing 2024 briefing! 👏 The report is a great read for those interested in the European quantum market, offering a full map of early-stage startups, deal sizes, and a ranking of the most active quantum computing investors - we're particularly excited to see our investors and partners Quantonation, European Innovation Council and SMEs Executive Agency (EISMEA), and Bpifrance featured as key players driving quantum innovation. Congratulations to them and all the funds making a difference! As we celebrate this recognition, we also want to thank our other investors Omnes and XAnge for your continued support in our journey 🙌 🔗 https://lnkd.in/eWRt8DFW #quantuminnovation #quantumaideddrugdesign #drugdiscovery #risingstar

Qubit Pharma at the 5th RAS Initiative Symposium! We’re excited to be attending this highly interactive forum, sharing the latest advancements in RAS research and connecting with our partners at Frederick National Laboratory for Cancer Research. What better way to kick off a partnership than meeting face-to-face with experts, while attending insightful sessions? "This 5th edition of the RAS Initiative Symposium by Frederick National Lab has been just as successful as its predecessors. The rich, meaningful exchanges with leaders in the field over the last few days, have provided so much to bring back to our teams in Paris and Boston." Thanks to Jay Ponder, co-founder at Qubit Pharmaceuticals and Professor at Washington University in St. Louis, Manon Réau, PhD Réau, Research Scientist, Thomas Lepitre and Sara Dolcetti, VP Business Development, for travelling all the way to Maryland! ⭐ Looking forward to building on these collaborations and innovations! #CancerResearch #QuantumAidedDrugDesign #RASResearch

👏 We are thrilled to announce that Anouar Benali has joined our team as the new Team Lead, High Performance Electronic Structure Theory. With over a decade of experience at Argonne National Laboratory, Anouar brings a wealth of expertise in computational science, particularly in the development and optimization of high-accuracy electronic structure methods. "I’m excited to join Qubit Pharmaceuticals, where a team of extraordinary scientists is united by a shared goal—designing life-saving drugs. Qubit Pharma's cutting-edge technology, combining classical and quantum computing, offers the perfect environment to apply and further develop the high-accuracy electronic structure methods I've worked on throughout my career. This new adventure is deeply meaningful to me and it's an incredible opportunity to contribute to the creation of transformative therapies." Anouar's deep experience in computational science will be instrumental as we continue to unlock the power of quantum to design novel molecules for complex targets. Join us in welcoming Anouar to the #QubitPharma team! #quantumaideddrugdesign #highaccuracyelectronicstructuremethod #quantumcomputing